VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue® Eye Care Recycling programs have colle…
Author: Business Wire
Warby Parker Publishes 2023 Impact Report
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today published its 2023 Impact Report. Each year, Warby Parker tracks and reports its impact on stakeholders fol…
Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA
BALTIMORE–(BUSINESS WIRE)–Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced today the completion of two successful and productive Pre-Submission meetings w…
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 202…
Glaukos Announces the Release of its 2023 Sustainability Report
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. B…
Walmart Health Expands in Texas with 18 New Locations
BENTONVILLE, Ark.–(BUSINESS WIRE)–Residents in Texas can experience affordable and integrated healthcare services all in one convenient location with the opening of three new Walmart Health centers in Pearland (10505 Broadway St, Pearland, TX), Sugar…
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first…
iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging
NEW YORK–(BUSINESS WIRE)– #AI–iPredictTM glaucoma detection model provides a fully automated detection report for glaucoma which can be implemented in the primary care settings for screening and detection of early-stage glaucoma. The full US patent …
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AMLX–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELI…
Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced…
Alcon Publishes Agenda for 2024 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2024 Annual General Meeting
拨康视云（Cloudbreak Pharma） 最新调查结果凸显眼疾负担，彰顯非手术治疗选项对于被低估和未充分治疗的翼状胬肉眼疾的重要性
加州尔湾–(BUSINESS WIRE)–(美国商业资讯)– 拨康视云是一家临床阶段的生物技术公司，致力于开发治疗常见但治療方案甚少的眼科疾病的药物。該公司在波士顿举行的年度ASCRS会议上分享了一项由公司支持的调查数据，该调查彰顯了翼状胬肉的患者负担。翼状胬肉是一种眼部疾病，通常被称为“冲浪者眼”，可能是暴露于高水平紫外线辐射環境而引起的。1 这项横断面调查显示，50％的受访者报告称翼状胬肉对他们的生活产生了相当大的影响，經常干扰他们进行日常活动的能力。2超过一半的受访患者还表示环境因素，如…
New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease
IRVINE, Calif.–(BUSINESS WIRE)–Cloudbreak Pharma, a clinical stage biotechnology company developing ophthalmic drugs for common eye diseases with few treatment options, shared new data from a company-supported survey highlighting the patient burden o…
Dry Eye Syndrome Market Set for Rapid Growth as Aging Population Demand Soars – Global Long-term Forecast to 2028 and 2032 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Syndrome Global Market Report 2024” report has been added to ResearchAndMarkets.com’s offering. This research publication sheds light on the robust growth and pivotal trends propelling the sector forward, ensuring …
Global Allergy Conjunctivitis Market Projected to Reach $3.2 Billion by 2028, Driven by Increasing Allergies and Technological Innovations – Long-term Forecast to 2032 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Allergy Conjunctivitis Global Market Report 2024” report has been added to ResearchAndMarkets.com’s offering. Market Expansion Driven by Increasing Allergies and Technological Innovations in Treatment The global allergy co…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (“GenSight Biologics” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for ret…
GenSight Biologics annonce son calendrier financier pour 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodé…
GenSight Biologics Announces its 2024 Financial Calendar
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…